CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.
CinCor Pharma to be Acquired by AstraZeneca
![](https://cinrx.com/wp-content/uploads/2023/01/cincor-tile.jpg)
CinCor Pharma, Inc. today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.
vTv Therapeutics Announces Investment by CinRx Pharma
![](https://cinrx.com/wp-content/uploads/2022/08/vtv-tile-1.jpg)
vTv Therapeutics Inc. today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”).